Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$315.34 +5.66%

+$18.29 today

Market cap
$9.34B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.35M

Average 0.29M

KRYS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Krystal Biotech, Inc.NASDAQ: KRYS

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue dips below year-ago levels

Q2 FY2026 cost of revenue of $6.44M fell 10.2% year over year, behind the +23.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1.8% from the prior quarter.

Context

  • Cost of revenue amounted to 7.4% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.2% toward the trailing-twelve-month pace of +23.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.44M+1.8% QoQ
Last fiscal yearDec 2025
$28.77M+43.4% YoY
LTMJun 2026
$29.34M+23.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.2%——
1 year+43.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
28.77M USD
Year-over-year change
+43.4%

Cost of Revenue vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 cost of revenue of $29.34M is the 2nd highest of the 6 companies compared; the peer median is $6.67M.
  • Its year-over-year change of +23.1% is the 3rd highest of 5, against a peer median of +65.5%.
  • Cost of revenue amounts to 6.7% of revenue for KRYS, versus a peer median of 48.1%.
KRYS Competitors Peer median
Cost of Revenue for KRYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGNXREGENXBIO Inc.LTM Mar 2026$87.94M +139.2%-28.1%100.1%
KRYSKrystal Biotech, Inc.LTM Jun 2026$29.34M +23.1%—6.7%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$6.99M +800.8%+50.4%48.1%
MGTXMeiraGTx Holdings plcLTM Mar 2026$6.67M -73.5%—8.4%
SANASana Biotechnology, Inc.LTM Mar 2026$2.39M ———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$2.15M -8.3%——
Peer median (excluding KRYS) $6.67M+65.5%+11.2%48.1%

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050.7M290.52M389.13M
Cost of Revenue003.09M20.06M28.77M
Gross Profit0047.61M270.45M360.36M
Gross Margin——93.9%93.1%92.6%
Research & Development27.88M42.46M46.43M53.57M58.05M
Selling, General & Admin40.39M77.74M98.4M113.69M146.74M
Operating Expenses68.28M145.2M157.33M204.76M199.06M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
EBITDA(65.31M)(116.14M)(92.22M)109.91M196.02M
EBITDA Margin——-181.9%37.8%50.4%
Operating Income(68.28M)(145.2M)(109.73M)65.7M161.3M
Operating Margin——-216.4%22.6%41.5%
Interest Income197K5.22M22.62M29.66M28.18M
Interest Expense1.49M0000
Other Income / Expenses(1.3M)5.22M122.62M29.66M28.18M
Income Before Tax(69.57M)(139.98M)12.9M95.36M189.47M
Pre-Tax Margin——25.4%32.8%48.7%
Income Tax Expense001.97M6.2M(15.36M)
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Net Margin——21.6%30.7%52.6%
EPS (Basic)(3.13)(5.49)0.403.127.08
EPS (Diluted)(3.13)(5.49)0.393.006.84
Weighted Avg Shares22.2M25.49M27.15M28.59M28.94M
Weighted Avg Shares (Diluted)22.2M25.49M27.75M29.74M29.95M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$315.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.